CA Patent

CA3205857A1 — Compositions and methods for treatment of skin cancers

Assigned to Simaomics Inc · Expires 2022-07-28 · 4y expired

What this patent protects

siRNA sequences for inhibiting ?GF? and Cox-2 gene expression are provided. Methods for treatment of skin cancers, in which pharmaceutical compositions or containing these siRNA agents and complexes, are further provided, in particular, for treating squamous cell carcinoma (isSCC…

USPTO Abstract

siRNA sequences for inhibiting ?GF? and Cox-2 gene expression are provided. Methods for treatment of skin cancers, in which pharmaceutical compositions or containing these siRNA agents and complexes, are further provided, in particular, for treating squamous cell carcinoma (isSCC) and/or basal cell carcinoma (BCC). ?GF? and Cox-2 have each been implicated in driving cancer progression. ?GF? is upregulated in a number of tumor types and plays a role in stimulating cancer-associated fibroblast development. Cox-2 upregulation plays a negative role in inducing inflammation and converting active T-cells to inactive T-reg cells. Co-delivery of the two siRNAs into the same cell at the same time silences of both targets at the same time results in anti tumoral activity.

Drugs covered by this patent

Patent Metadata

Patent number
CA3205857A1
Jurisdiction
CA
Classification
—
Expires
2022-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Simaomics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.